Last reviewed · How we verify
NCT03526523
Testing the Efficacy of Mindfulness-based Stress Reduction in the Prevention of Perimenopausal Depression
NA trial testing Mindfulness-based stress reduction in Perimenopausal Depression in 104 participants. Completed in 20 March 2020.
20 March 2020
Quick facts
| Lead sponsor | University of Regina |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 104 |
| Start date | 5 July 2018 |
| Primary completion | 20 March 2020 |
| Estimated completion | 20 March 2020 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Mindfulness-based stress reduction
Conditions studied
- Perimenopausal Depression — all drugs for Perimenopausal Depression →
- Depressive Symptoms — all drugs for Depressive Symptoms →
Sponsor
University of Regina
Who can join
Adults 42 to 55, female only, with Perimenopausal Depression or Depressive Symptoms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Depression is the leading cause of disability worldwide and a risk factor for other diseases. While women are at elevated risk for depression in general, the menopause transition is a particularly vulnerable time for many women, with the risk for depression increasing 2-4 fold. The objective of this research study is to determine whether mindfulness-based stress reduction (MBSR), an 8-week structured intervention involving meditation and yoga, has any beneficial mood effects for women undergoing this vulnerable time.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03526523
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mindfulness-based stress reduction
Trials testing the same drug.
- NCT05837169 — Randomized Study to Evaluate an Intervention Based on Mindfulness to Reduce Anxiety in Breast Cancer Survivors · NA · completed
- NCT05715372 — Genetic Evaluation and Modification of Lifestyles to Improve Female Life Expectancy · NA · terminated
- NCT04842097 — Online Mindfulness-based Stress Reduction Intervention for People With Chronic Pain Waiting for Health Services · NA · completed
- NCT07082491 — Mindfulness for Reducing Work-Related Stress · NA · completed
- NCT04867967 — Yoga and MBSR for TTH · NA · completed
Other University of Regina trials
Trials by the same sponsor.
- NCT06020274 — Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, Resource Program: How Does it Work? · NA · not yet recruiting
- NCT07021053 — Adaptive Actions and Alcohol Use Outcomes During Internet-delivered Cognitive Behaviour Therapy · NA · recruiting
- NCT07021183 — The Public Safety Personnel (PSP) Sleep Course: An Online Sleep Intervention for PSP. · NA · recruiting
- NCT06881693 — Internet-Delivered Cognitive Behaviour Therapy for Depression and Anxiety in Perinatal Parents · NA · recruiting
- NCT06606704 — Effects of Resistance-band Training and Creatine Supplementation Strategies in Healthy Older Adults · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03526523 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Regina
- Last refreshed: 6 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03526523.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing